Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...
Full approval was driven by BREAKWATER Phase III outcomes, including PFS HR 0.53 and OS HR 0.49 versus fluoropyrimidine/oxaliplatin-based chemotherapy options ± ...
Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...
BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in progression-free survival in BRAF V600E-mutant metastatic colorectal cancer Results ...
Clinical utility may be greatest with careful patient selection, given frailty-associated toxicity and potential endpoint ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI ® (encorafenib) in combination with cetuximab ...
On 24 February 2026, Pfizer reported that the U.S. FDA granted full approval for BRAFTOVI (encorafenib) plus cetuximab and ...
Ipsen receives CHMP’s positive opinion on Ojemda for treating monotherapy of children with relapsed or refractory BRAF-altered paediatric low-grade glioma: Paris Wednesday, Marc ...
As nonprofit-governed Servier continues to make gains with its IDH-mutant glioma med Voranigo, the drugmaker is wading deeper ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results